Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a risky play for even the most confident investor. Share prices gave a glimmer of hope recently …
Valeant Still Has Higher Risk Profile Despite ‘Solid’ Q2 Results Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares crashed 10% yesterday after the troubled biotech …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) confirms that Paulson & Co., Inc.
Valeant’s Strengths Are Laced with Challenges Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivered a sound second-quarter print yesterday before the bell- but the troubled …
Mizuho analyst Irina Rivkind Koffler came out today with new research notes on a handful of biotechnology stocks. Let’s take a look and …
Valeant’s a Deep Shade of Grey All eyes are on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as the Street wonders if this troubled biotech …
Valeant Pharmaceuticals Intl Inc Valeant (NYSE:VRX) is due to report its earnings results for the second quarter this morning. FactSet consensus reveals that …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced it has received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) …
Valeant May Post Weak 2Q Print- But Might Not Dent Investor Sentiment After All Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivers its second-quarter print …
Is Teva Pharmaceutical a Falling Knife to Catch After Plunging over 30%? This week turned out to be a nightmare for shareholders of Teva …